Investors

Transforming oral drug development with Formulite®

Disruptive Pharma is a Swedish clinical-stage pharmaceutical development company focused on improving oral drug performance through our proprietary Formulite®platform. Built on a clinically validated amorphous formulation technology, Formulite addresses one of the most persistent challenges in drug development: poor oral bioavailability.

The company combines a scalable, IP-protected technology platform with a selective pipeline of added-value drug product candidates and technology-driven partnering. Operating with a capital-efficient model, Disruptive Pharma targets attractive partnering and licensing opportunities across multiple therapeutic areas.

Disruptive Pharma’s value creation is centred around Formulite, designed to improve oral drug performance and manufacturability.

Investment highlights

  • Strong industry demand: Growing need for alternatives to established bioavailability enhancement technologies
  • Addressing a key challenge: Formulite solves one pharma’s largest challenges: Poor oral bioavailability
  • Clinically validated: Approved and safe for human use
  • Scalable platform business: Formulite enables multiple revenue streams across product candidates, partnerships, and services
  • Partner traction: Ongoing projects with Big Pharma, biotechs, specialty pharma and manufacturers
  • Future opportunity: Reinvest revenue in own pipeline programs , improved versions of marketed drugs

Bolagsstyrning

Totalt finns det 1 003 710 aktier i bolaget varav 104 983 aktier registrerades vid bolagets bildande samt totalt 898 727 aktier registrerades i samband med nyemissioner i juli 2021, juli 2022, maj 2024 och juli 2025. Samtliga aktier har ett kvotvärde på 4,76 SEK och lika röstvärde.

STYRELSE
LEDNING
VALBEREDNING
BOLAGSORDNING
BOLAGSTYNINGSRAPPORT
BOLAGSSTÄMMOR

Aktien och ägare

Totalt finns det 1 003 710 aktier i bolaget varav 104 983 aktier registrerades vid bolagets bildande samt totalt 898 727 aktier registrerades i samband med nyemissioner i juli 2021, juli 2022, maj 2024 och juli 2025. Samtliga aktier har ett kvotvärde på 4,76 SEK och lika röstvärde.

Ägare 31 juli 2025 ->
Företrädesemission juni 2025 ->
Företrädesemission april 2024 ->

Kontakt

Investerarkontakt

Peter Åsberg